Liss' Lowdown #37

Preclinical Breakthrough of the Month:

Polyrizon Launches Preclinical Trial for Nasal Spray Seizure Treatment

Polyrizon Ltd. has started early-stage testing on a new nose spray version of Benzodiazepines (BZDs), a common medication used to stop serious seizures. The goal is to create a fast-acting treatment that can be used quickly and easily during a seizure emergency, even outside of a hospital.

The research is being done in partnership with Professor Fabio Sonvico from the University of Parma , an expert in nasal drug delivery. Instead of using injections or pills, this treatment would be sprayed into the nose. This method could help the medicine work faster by reaching the brain more directly and could be used by caregivers or first responders without needing medical training.

BZDs are already used to treat seizures, but giving them quickly and safely in real-life emergencies can be a challenge. This nose spray could make a big difference by saving precious time and helping people get the medication they need right away.

This is still in the early testing phase, but if it works well, it could offer a new and more practical way to treat seizures, especially for people who need help fast and outside of medical settings.

Clinical Breakthrough of the Month:

Clinical Trials Day 2025 – A Quick Nod to the People Behind the Progress

May 20th marked Clinical Trials Day – a chance to recognise the incredible people driving clinical research forward. The date commemorates James Lind’s landmark scurvy trial aboard a British naval ship in 1747, widely regarded as the first controlled clinical trial in history. From that pivotal moment to today’s complex, global studies, this day is all about acknowledging how far we’ve come, and the people making it happen.

Every successful study owes thanks to a huge network of professionals: trial participants, CRAs, data managers, project leads, site staff, medical monitors, and many more. Whether you’re managing start-up timelines, cleaning data, or coordinating trials across multiple regions – your role is critical to advancing treatments and improving lives.

Partnership of the Month:

Julius Clinical and Peachtree BioResearch Solutions Merge to Form Global CRO

Julius Clinical , a full-service Dutch CRO, and Peachtree BioResearch Solutions a Julius Clinical Company , a US-based CNS specialist CRO, have merged to form a fully integrated global clinical research organization. This strategic union combines nearly a decade of collaboration, expanding their operational footprint and deepening therapeutic expertise - especially in central nervous system, cardio-metabolic, renal, and rare diseases.

The merger strengthens their Phase I–III capabilities, offering end-to-end services to pharma, biotech, and medical device companies across Europe and North America.

"This is a natural evolution of our long-standing relationship," said Martijn W. , CEO of Julius Clinical. "Together, we enhance our flexibility and global reach." Kristy Nichols , CEO of Peachtree, added, "We’re preserving our personal touch while gaining broader capabilities for our clients."

Backed by Ampersand Capital Partners , the combined entity is positioned to meet the growing demands of complex, global clinical research.